JP2024506942A5 - - Google Patents
Info
- Publication number
- JP2024506942A5 JP2024506942A5 JP2023549823A JP2023549823A JP2024506942A5 JP 2024506942 A5 JP2024506942 A5 JP 2024506942A5 JP 2023549823 A JP2023549823 A JP 2023549823A JP 2023549823 A JP2023549823 A JP 2023549823A JP 2024506942 A5 JP2024506942 A5 JP 2024506942A5
- Authority
- JP
- Japan
- Prior art keywords
- citrate
- hemy
- compound
- pharmaceutical composition
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150782P | 2021-02-18 | 2021-02-18 | |
| US63/150,782 | 2021-02-18 | ||
| PCT/US2022/016612 WO2022178000A1 (en) | 2021-02-18 | 2022-02-16 | Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506942A JP2024506942A (ja) | 2024-02-15 |
| JP2024506942A5 true JP2024506942A5 (https=) | 2025-02-25 |
Family
ID=82931143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549823A Pending JP2024506942A (ja) | 2021-02-18 | 2022-02-16 | Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20240190910A1 (https=) |
| EP (1) | EP4294819A4 (https=) |
| JP (1) | JP2024506942A (https=) |
| TW (1) | TW202245790A (https=) |
| WO (1) | WO2022178000A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| EP4514357A4 (en) * | 2022-04-26 | 2026-04-29 | Praxis Prec Medicines Inc | METHODS OF TREATING NEUROLOGICAL DISORDERS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004072079A1 (en) * | 2003-02-11 | 2004-08-26 | Pfizer Limited | Hydrated and anhydrous sildenafil hemi-citrate compound |
| US20060074059A1 (en) * | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| ATE538797T1 (de) * | 2005-06-09 | 2012-01-15 | Euro Celtique Sa | Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon |
| US10562930B1 (en) * | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
-
2022
- 2022-02-16 EP EP22756844.1A patent/EP4294819A4/en active Pending
- 2022-02-16 JP JP2023549823A patent/JP2024506942A/ja active Pending
- 2022-02-16 WO PCT/US2022/016612 patent/WO2022178000A1/en not_active Ceased
- 2022-02-16 US US18/546,800 patent/US20240190910A1/en active Pending
- 2022-02-17 TW TW111105875A patent/TW202245790A/zh unknown
- 2022-05-25 US US17/824,205 patent/US11697669B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024202835A1 (en) | Polymorphs of selinexor | |
| JP2024178291A (ja) | （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム | |
| TW201408661A (zh) | 抗病毒性化合物之固體形式 | |
| TW200827326A (en) | Organic compounds | |
| TW200924786A (en) | Certain compounds, compositions and methods | |
| JP2024506942A5 (https=) | ||
| CN107567444A (zh) | 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物 | |
| JP2023103328A (ja) | ビランテロールトリフェニル酢酸塩の新規な結晶形態及びこれらの調製プロセス | |
| CN105189513A (zh) | 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态 | |
| JP2023523770A5 (https=) | ||
| CN103833712B (zh) | 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途 | |
| JP2014051517A (ja) | デフェラシロックス（ｉｃｌ６７０ａ）の多形形態 | |
| JP2000514096A (ja) | 炭素環式ヌクレオシドヘミスルフェートおよびウイルス感染症の治療におけるその使用 | |
| JP7854206B2 (ja) | 肺線維症の予防または治療用の薬学製剤 | |
| US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
| AU2014361794B2 (en) | Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof | |
| CN101282968B (zh) | 多晶态形式和非晶态形式的5-氯-n-({(5s)-2-氧-3-[4-(3-氧-4-吗啉基)-苯基]-1,3-*唑烷-5-基}-甲基)-2-噻吩羧酰胺 | |
| CN102282125A (zh) | 新方法和纯的多晶型物 | |
| CN1214029C (zh) | 4－氨基－6,7－二甲氧基－2－(5－甲磺酰氨基－1,2,3,4－四氢异喹啉－2－基)－5－(2－吡啶基)喹唑啉甲磺酸盐及多晶形物 | |
| JP5888612B2 (ja) | 縮合ピリジン化合物塩の結晶 | |
| CN107056819B (zh) | 一种预防和治疗心肌缺血的药物及其制备方法 | |
| JP2018537469A5 (https=) | ||
| JP7788550B2 (ja) | ターフェニル化合物の安息香酸塩の製造方法 | |
| TW201609788A (zh) | 類固醇樣化合物之多晶型形式以及其製備方法及用途 | |
| HK40092799A (zh) | Pn6047盐酸盐的多晶型物 |